Lirit N Franks
Overview
Explore the profile of Lirit N Franks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shoeib A, Yarbrough A, Ford B, Franks L, Urbaniak A, Hensley L, et al.
Life Sci
. 2021 Sep;
285:119993.
PMID: 34592231
Aims: Characterizing cannabinoid receptors (CBRs) expressed in Ewing sarcoma (EWS) cell lines as potential targets for anti-cancer drug development. Main Methods: CBR affinity and function were examined by competitive binding...
2.
Ford B, Cabanlong C, Tai S, Franks L, Penthala N, Crooks P, et al.
J Pharmacol Exp Ther
. 2019 Mar;
369(2):259-269.
PMID: 30833484
Most cannabinoid 1 receptor (CBR) agonists will signal through both G protein-dependent and -independent pathways in an unbiased manner. Recruitment of -arrestin 2 desensitizes and internalizes receptors, producing tolerance that...
3.
Hutchison R, Ford B, Franks L, Wilson C, Yarbrough A, Fujiwara R, et al.
Front Pharmacol
. 2018 Oct;
9:1084.
PMID: 30319418
Recreational use of marijuana is associated with few adverse effects, but abuse of synthetic cannabinoids (SCBs) can result in anxiety, psychosis, chest pain, seizures and death. To potentially explain higher...
4.
Franks L, Ford B, Fujiwara T, Zhao H, Prather P
Toxicol Appl Pharmacol
. 2018 Jun;
353:31-42.
PMID: 29906493
Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several SERMs exhibit anti-cancer activity not related to ERs. To discover novel anti-cancer drugs acting...
5.
Ford B, Franks L, Tai S, Fantegrossi W, Stahl E, Berquist M, et al.
Pharmacol Res
. 2017 Aug;
125(Pt B):161-177.
PMID: 28838808
The human cannabinoid subtype 1 receptor (hCBR) is highly expressed in the CNS and serves as a therapeutic target for endogenous ligands as well as plant-derived and synthetic cannabinoids. Unfortunately,...
6.
Franks L, Ford B, Prather P
Front Pharmacol
. 2017 Jan;
7:503.
PMID: 28066250
Selective estrogen receptor modulators (SERMs) are used to treat estrogen receptor (ER)-positive breast cancer and osteoporosis. Interestingly, tamoxifen and newer classes of SERMs also exhibit cytotoxic effects in cancers devoid...
7.
Ford B, Franks L, Radominska-Pandya A, Prather P
PLoS One
. 2016 Dec;
11(12):e0167240.
PMID: 27936172
Tamoxifen (Tam) is a selective estrogen receptor (ER) modulator (SERM) that is an essential drug to treat ER-positive breast cancer. Aside from known actions at ERs, recent studies have suggested...
8.
Franks L, Ford B, Madadi N, Penthala N, Crooks P, Prather P
Eur J Pharmacol
. 2014 May;
737:140-8.
PMID: 24858620
Our laboratory recently reported that a group of novel indole quinuclidine analogs bind with nanomolar affinity to cannabinoid type-1 and type-2 receptors. This study characterized the intrinsic activity of these...
9.
Prather P, FrancisDevaraj F, Dates C, Greer A, Bratton S, Ford B, et al.
Biochem Biophys Res Commun
. 2013 Oct;
441(2):339-43.
PMID: 24148245
Tamoxifen (Tam) is classified as a selective estrogen receptor modulator (SERM) and is used for treatment of patients with ER-positive breast cancer. However, it has been shown that Tam and...
10.
Vasiljevik T, Franks L, Ford B, Douglas J, Prather P, Fantegrossi W, et al.
J Med Chem
. 2013 May;
56(11):4537-50.
PMID: 23631463
Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a new therapeutic direction for treatment of alcohol abuse. We have recently reported that a monohydroxylated metabolite of...